Proactiveinvestors recommends

Red Sky Energy sees upside potential as New South Wales decision on Talma CSG pilot draws near
Xceed Resources: Cash backed and developing coal production and cash flows from Moabsvelden
Oro Verde on the exploration trail of gold and copper in Chile, commences trading today

Additional Information

Market:	ASX
Sector:	Aerospace
EPIC:	HTX
Latest Price:	0.01 (-9.09% )
52-week High:	0.08
52-week Low:	0.01
Market Cap:	2.18M

1 year chart

1 day chart

HealthLinx

HealthLinx (ASX: HTX) is an emerging biomarker and diagnostic company with an integrated platform in biomarker and bioactive peptide discovery platforms.

The company develops novel, non-invasive, serum-based, diagnostic products.

HealthLinx Ltd launches ovarian cancer test into UK market

Wednesday, February 24, 2010

HealthLinx (ASX: HTX) has reported that UK distribution partner Intus Healthcare is targeting a significant share of the potential 750,000 annual ovarian cancer diagnostic tests undertaken in the UK with the product launch of OvPlex™ on 25 February 2010.

The company obtained European Certification for OvPlex™ paving the way to market and sell the product within the European community.

Nick Gatsios, managing director of HealthLinx said the UK launch will be the first large scale roll out of OvPlex™ and HealthLinx will receive a royalty of approximately $70 per test.

The UK marketing launch of OvPlex™ on such a large scale will build a platform for HealthLinx to target other countries.

The company has opened discussions in Korea, China, other European countries for OvPlex™ and has been approached by some Central South American countries, providing strong commercial upside opportunities.

The recent announcement that OvPlex™ was awarded BioSpectrum Product of the Year in Asia Pacific for 2010 by an independent jury chaired by Dr G Steven Burrill of Burrill and Co, further supports the commercial opportunity for the product.

Each year 240,000 new cases of ovarian cancer are diagnosed worldwide and over 130,000 women die from the disease. The UK region accounts for over 7,000 of these diagnoses and 4,000 lives lost per year.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.